Pure Global

Safety of ENC-201-CED ENCRT - Trial NCT06408311

Access comprehensive clinical trial information for NCT06408311 through Pure Global AI's free database. This Phase 1 trial is sponsored by Encellin and is currently Recruiting. The study focuses on Diabetes Mellitus, Type 1. Target enrollment is 10 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06408311
Phase 1
Recruiting
combination product
Trial Details
ClinicalTrials.gov • NCT06408311
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Safety of ENC-201-CED ENCRT
A Safety and Tolerability Study of ENC=201-CED in Participants With Type 1 Diabetes Receiving Islet Infusion

Study Focus

Diabetes Mellitus, Type 1

ENC-201-CED hPI

Interventional

combination product

Sponsor & Location

Encellin

Montréal, Canada

Timeline & Enrollment

Phase 1

May 01, 2024

Jun 30, 2026

10 participants

Primary Outcome

Safety

Summary

The purpose of the study is to evaluate the safety and tolerability of ENC-201-CED in a
 subcutaneous space in patients with Type I diabetes.

ICD-10 Classifications

Type 1 diabetes mellitus
Type 1 diabetes mellitus with unspecified complications
Type 1 diabetes mellitus with other specified complications
Type 1 diabetes mellitus without complications
Type 1 diabetes mellitus with multiple complications

Data Source

ClinicalTrials.gov

NCT06408311

Non-Device Trial